Breaking News, Financial News

Financial Reports: Covance 1Q

Early Development slowdown leads to restructuring

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Covance 1Q12 1Q Revenues: $531 million (+7%) 1Q Earnings: $36 million (+9%) Comments: Early Development Services dropped 6% to $212 million due to lower than expected volumes in box and discovery support services, while Late-Stage Development was up 15% to $319 million with a 25% growth in clinical development and 4% uptick in central laboratory services. The company announced plans to close a facility in Chandler, AZ and engage in other Early Development restructurings to improve earnings by...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters